In early March, Eli Lilly made headlines after announcing a new $35 price cap on insulin for individuals with private insurance. Novo Nordisk and Sanofi made their own price reduction announcements shortly after Eli Lilly’s move.
Tag: insulin access
Endocrine Society praises State of the Union attention to insulin affordability
The Endocrine Society applauds President Biden’s call to rein in soaring insulin prices for those with private insurance and urges Congress to take immediate action.
Endocrine Society celebrates passage of historic insulin affordability measure
The Endocrine Society cheered the Senate’s passage of the Inflation Reduction Act, including meaningful measures to make insulin more affordable.
Endocrine Society celebrates House passage of Build Back Better Act
The Endocrine Society hailed the House of Representatives for including provisions to improve insulin affordability in its version of the Build Back Better Act.
Endocrine Society calls on Congress to pass legislation to lower the price of insulin
The Endocrine Society is calling on Congress to pass legislation to lower the price of insulin and applauds the efforts of Energy and Commerce Committee Chairman Frank Pallone Jr. (D-NJ), Ways and Means Committee Chairman Richard E. Neal (D-MA), and Education and Labor Committee Chairman Robert C. “Bobby” Scott (D-VA) to reintroduce H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act to improve access to affordable medications. In January, the Society published a position statement on insulin access and affordability, which recommends policymakers include government negotiation as part of an overall strategy to reduce insulin prices.
People with Type 1 Diabetes Spend About $2,500 a Year in Health Care Costs
Adults and children with type 1 diabetes will spend an average of $2,500 a year out-of-pocket for health care – but insulin isn’t always the biggest expense – new research suggests
Wearable delivery device allows patients with type 2 diabetes to safely use more affordable insulin option
Adults with type 2 diabetes requiring insulin therapy can safely achieve good blood sugar control using regular human insulin (RHI) in a wearable, patch-like insulin delivery device called V-Go®, a new study finds. Results of the randomized controlled study—which was accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and will be published in a special supplemental section of the Journal of the Endocrine Society—suggest “a more affordable option” for insulin therapy than newer insulin types, the researchers said.